Cuprina Holdings, a Singapore-based company, has secured a second FDA clearance for its therapeutic larvae, MediFly Maggots, this time for the Lucilia cuprina species, also known as the Australian sheep blowfly. This makes Cuprina the sole company to hold FDA clearance for two distinct species of fly larvae used in maggot debridement therapy (MDT), a significant step towards its goal of global market dominance in wound care.
The company's CEO, David Quek, stated that this dual clearance anchors their wound-care platform in a demanding regulatory market and provides a defensible edge. While Cuprina does not claim significant therapeutic differences between the two species, they are seen as catering to different market preferences. Lucilia sericata, the common green bottle fly, is more familiar in Western wound care, whereas Lucilia cuprina has a recognized international track record.
Ronald Sherman, Cuprina's Medical and Scientific Director and a long-time proponent of maggot therapy, hailed the clearance as a positive development for MDT, offering clinicians and patients greater flexibility. The FDA first granted clearance for L. sericata in 2004. Despite its historical use and potential benefits in cleaning wounds and stimulating tissue regrowth, maggot therapy remains a niche treatment due to the "ick" factor and a lack of robust clinical evidence. The article also touches upon accidental maggot infestations (myiasis) and a novel extraction method using uncooked bacon strips.
